Drug Manufacturers - General
🏛 Recent congressional trades
“PFE pulled back 1.2% on Friday, but this is a minor breather within a strong uptrend. The stock has rallied 6.3% over the past month and 9.3% over three months, trading well above its 50-day moving average and near 52-week highs at the 87th percentile. No obvious stock-specific catalyst for the dip; likely profit-taking after the run-up. The upward momentum remains intact. Pullbacks toward the 50-day line could offer entry points for longer-term investors, given the favorable trend.”
Updated 09-07 22:26
The Fed's FOMC meeting on September 16-17, 2026 is expected to deliver another rate cut, with the federal funds rate already in the 3.50%-3.75% range; lower rates modestly support PFE's dividend yield appeal (~6.05%) but have limited direct impact on pharma fundamentals.
The April 2026 Executive Order imposing 100% tariffs on patented pharmaceuticals took effect for large companies on July 31 and will expand to all others on September 29, 2026, creating supply chain uncertainty for Pfizer's global API sourcing, though Pfizer has negotiated MFN pricing agreements with the administration to mitigate some exposure.
Pfizer is executing a high-stakes pivot to oncology and obesity through its $43B Seagen acquisition and $10B Metsera deal, with 20+ obesity studies including 10 Phase 3 trials for monthly GLP-1 berobenatide targeting 2028 approval, while non-COVID oncology products (Lorbrena +37%, Padcev +23%, Eliquis +19%) drove 18% operational growth in Q2.
Pfizer faces a $17B patent cliff between 2026-2030 as Eliquis loses European exclusivity (May 2026) and approaches US patent expiry (November 2026), with Ibrance, Xtandi, and Prevnar also facing generic competition, creating significant revenue headwinds.
Healthcare sector rotation is accelerating in 2026 as investors shift from concentrated tech into defensive value names, with PFE up 20.15% YTD (vs. S&P 500 +12.75%) and trading near its 52-week high of $29.21, benefiting from its low forward P/E of ~9.9x and strong cash flow profile.
Pfizer reported strong Q2 2026 earnings on August 4 with revenue of $15.03B (beat vs. $14.55B estimate) and adjusted EPS of $0.77 (beat vs. $0.69), raised FY2026 revenue guidance to $60.5-$62.5B, and CEO Albert Bourla purchased ~$1M in shares on August 11, signaling management confidence.
Updated 09-07 22:26
Updated 09-07 22:26